Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02883140
Other study ID # RC15_0196
Secondary ID
Status Completed
Phase
First received
Last updated
Start date June 23, 2016
Est. completion date August 31, 2019

Study information

Verified date September 2022
Source Nantes University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Non tumor salivary gland diseases are common and include sialadenitis, sialadenosis, stones, stricture and ductal dilatation, anatomical abnormalities. A radiological examination is required in order to sign the diagnosis, locate precisely the lesions and define the therapeutic strategy. Cone beam computerized tomography (CBCT), because of its accessibility and the possibilities it offers in terms of image processing, is a potential alternative to the conventional sialography and to the MRI sialography, considered as a gold standard procedure. Our comparative study, aims to evaluate the diagnostic performance of the 3D-CBCT sialography compared to MRI sialography, in patients with non tumor ductal salivary diseases.


Description:

Our study focuses on patients over 18 years, with unilateral or bilateral parotid or submandibular salivary symptoms. Each patient included is given a MRI sialography and a 3D-CBCT sialography at a later stage when the acute episode has subsided. Images are archived on the Carestream Picture Archiving Communication System (PACS). Interpretation is achieved after Multi-Planar Reconstruction (MPR), Maximal Intensity Projection (MIP) and three-dimensional rendering. A primary radiological analysis of the two procedures is systematically done by a specialist radiologist for the diagnostic and therapeutic care of the patient. A second radiological data analysis is carried out at the end of the study, by a specialized radiologist, different from the first one, to asses the two radiological examinations. The primary outcome measure is the capability of the radiological technique to detect a ductal salivary feature. Secondary outcomes include the clinical characteristics of the patients, the diagnostic capabilities in identifying the salivary lesions, their number, their precise location and measurements. A primary side effect in catheterization and dosimetric parameters for the CBCT technique will be systematically recorded.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date August 31, 2019
Est. primary completion date August 18, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female, over 18 years old. - With unilateral or bilateral parotid or submandibular salivary symptoms (salivary swelling, salivary colic, pain, salivary infections), with an acute evolution (<14 days), subacute (2-12 weeks) or chronic one (>3 months). - With or without initial imaging (ultrasonography). - Understanding the technique and its interest in the diagnostic and therapeutic management. - Accepting the examination and the salivary catheterization. - Positive catheterization test Exclusion Criteria: - Patient whose physical or mental condition make him unable to understand the examination and to consent to the study. - Allergy to iodine. - Salivary infection under treatment. - Damage to the oral mucosa preventing salivary catheterization. - Contraindication to MRI: metal or valvular prosthesis, pacemaker, claustrophobia. - Current or suspected pregnancy. - Patient refusing the examination or the catheterization. - Salivary symptoms of tumor appearance: Unilateral palpable mass, facial palsy, multiple lymph nodes in parotid and / or pre-auricular and / or neck areas. - Salivary neoplasm demonstrated by a prior diagnostic testing. - Patient who underwent head and neck scan in the previous 6 months. Conventional or three dimensional sialography achieved in the previous 6 months. - Salivary catheterization failure.

Study Design


Related Conditions & MeSH terms

  • Non Tumor Salivary Gland Diseases of the Parotid Glands
  • Non Tumor Salivary Gland Diseases of the Submandibular Glands
  • Salivary Gland Diseases

Intervention

Other:
Three-dimensional sialography CBCT and MRI sialography
MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo). 3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Nantes University Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Detection of a salivary ductal disease with the 3D-CBCT sialography and the MRI sialography: Yes/No. 1 day
Secondary Precise location of lesions in the ductal system, identified as CSx for the Stensen's duct divisions and CWx for the Wharton's duct divisions (where CS1 and CW1 correspond to the main Stensen's and Wharton's ducts respectively) 1 day
Secondary Identification of the last salivary duct division visualized, identified as CSx for the Stensen's duct divisions and CWx for the Wharton's duct divisions 1 day
Secondary Operational safety: Looking for adverse effects of the catheterization (pain, bleeding, ductal perforation) 1 day
Secondary Dose Area Product (mGy.cm-2) for 3D-CBCT sialography 1 day